Tag Archives: RESI

Who Will You Meet at RESI San Francisco?

7 Jan

By Cole Bunn, Research Analyst, LSN

cole-wp

Life Science Nation’s mission of connecting scientist entrepreneurs with capital gave rise to the Redefining Early Stage Investments (RESI) conference nearly 3 years ago. As we approach our seventh RESI conference, during the highly anticipated JP Morgan week in San Francisco, we’re expecting a record of well over 300 investors representing over 200 different firms in attendance. Figure 1 shows a breakdown of investors by type who will be at RESI San Francisco on January 12, 2016. You can also view the firms represented here.

Venture capital is the most represented investor type, and this includes a growing number of non-traditional venture firms in today’s investment landscape. For instance, the relatively new emergence of the “micro VC” has more capital flowing into seed and series A stage companies. As shown here, several other investor classes looking for early-stage life science technologies that don’t fall under the venture capital umbrella also have a large presence at the RESI conference. This diversity of investors means that RESI Partnering can provide RESI’s great variety of attendees with the opportunity to make a connection with a financing partner that’s the right fit for their round.

Life Science Nation’s network of varied investor types will be showcased on an assortment of panels throughout the day. The 16 panels scheduled to take place at RESI San Francisco will cover the full range of companies in the life science space (biotech, medtech, diagnostic and health IT) and the different investor class’ tactical guidance for navigating the investment process of their respective niches and outlook on the future of each sector. The LSN research team’s unique perspective on the investment landscape has spurred a new panel that will be held for the first time at RESI San Francisco, Consumer Health “Investing in Innovative Products for Healthy Living,” and the return of two panels from former RESI events, Asia-Pacific Investors, “Forging Cross-Border Collaborations in Healthcare,” and Orphan & Rare Disease Investors, “Seeking Returns On Investing In Small Patient Populations”.

The fundraising process is typically a lengthy one, therefore multiple interactions with prospective investors and strategic partners are essential to a successful campaign. The RESI conference is an ongoing series that provides just that, allowing entrepreneurs to interface with a diverse field of investors, foster existing relationships and make new connections throughout the year, at multiple events. RESI San Francisco is just the first stop for 2016, with additional RESI conferences being held in Houston, Toronto and Boston, later in the year.

This ongoing chain of conferences coupled with the forward-looking investor mandate information used in our partnering platform really makes RESI stand out in terms of the ability to make meaningful connections. To see a demonstration of just how effective the partnering system can be at finding a match, please watch this video.

Tags: , ,

Redefining Early Stage Investments (RESI) Conference: Corporate VCs & Strategic Investment Panel

7 Jan

By Christine A. Wu, Research Analyst, LSN

chrsitine

At LSN’s RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.

In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.

Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:

  • Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
  • Geeta Vemuri, Vice President, Head, Baxalta Ventures
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Ilan Zipkin, Senior Investment Director, Takeda Ventures

If you’re a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before it’s too late.

RESI-San-Francisco-2016

Tags: , , , , ,

RESI Innovation Challenge: Participating Startups Announced

17 Dec

By Dennis Ford, Founder & CEO, LSN

dennis-websit

The RESI Innovation Challenge received a record number of applicants this fall. LSN’s scientific review board assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. We’d now like to announce these successful applicants. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. We’re excited to meet all these companies in person in the Exhibitor Hall at RESI, and we hope you’ll join us there to vote for the very best of these cutting-edge life science startups.

IC Logos SF2016

Tags: , , ,

Redefining Early Stage Investments (RESI) Conference: Healthcare IT Investors Panel

17 Dec

By Shaoyu Chang, MD, MPH,  Senior Research Manager, LSN

Shaoyu 10*10

At the intersection between life science and computer science, healthcare IT continues to attract strong interests from both camps. VC funds, big pharmas, and tech corporates are all actively seeking the next big thing in HCIT that would transform healthcare fundamentally.

Some of the biggest players in HCIT investment will speak at RESI San Francisco to share their expertise and advice with entrepreneurs. Moderated by Anne DeGheest, Founder of HealthTech Capital, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these HCIT investors – How do you make your company stand out in this crowded marketplace? What do investors see as the most high-potential fields of innovation in healthcare IT? How do you demonstrate to an investor that your product has the potential to succeed?

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , ,

Redefining Early Stage Investments (RESI) Conference: Orphan & Rare Disease Investors Panel

10 Dec

By Christine A. Wu, Research Analyst, LSN

chrsitine

The orphan and rare disease space has gained significant traction among life science investors. Despite the smaller market populations and limited clinical trial participants in rare diseases, technology in this space has remained attractive to investors due to its expedited FDA process and its lack of current treatment options for such uncommon conditions. Overall, while there are many challenges, there remains a lot of hope to drastically impact patient populations, scientific advancement, and market potential.

RESI San Francisco will bring together well-established investors in the rare and orphan disease space on January 12th. Moderated by Mark Day, Executive Director and Head of External Research & Scouting of Alexion Pharmaceuticals, panelists will include:

Panelists will discuss the attractiveness of orphan and rare disease technologies in comparison to non-orphan opportunities; what the rare disease spaces offers to investors; the best way to position an orphan opportunity to a potential investor; the evaluation process in assessing products in the space; as well as common trends, challenges, and excitement in the scientific advancement of the field.

To all the hopefuls in the orphan and rare disease space, this panel is for you. Register for RESI San Francisco now to hear this panel live – partnering has already begun and this event will be LSN’s biggest RESI yet.

RESI-San-Francisco-2016

Tags: , , , ,

Heighten Your Visibility at the Redefining Early Stage Investments Conference (RESI)

3 Dec

By Dr. William Kohlbrenner, CSO, LSN

bill-1010-2wp

JPM turns San Francisco into an industry hub every January, and it’s strategically vital to make your company shine during the biggest and busiest yearly event attended by investors and life science entrepreneurs.  While there are many conferences and receptions taking place, there are relatively few opportunities for promoting your company’s brand among qualified life science investors.

That’s why we designed the RESI Innovation Challenge to provide a better showcase for life science companies. By providing space in the RESI Exhibit Hall for successful applicants to place poster displays, the RESI Innovation Challenge puts your brand out there throughout the full-day event, keeping you on view for the hundreds of investors who will be attending RESI throughout the day. More importantly, your message will provide a talking point that can springboard conversations about your technology, your market opportunity, and your company’s progress. Even if you’re out doing a full tour of meetings, your message will still be getting out there in the RESI Exhibit Hall. If you place in the top 3 participating companies, LSN will also showcase you online in Next Phase.

With the RESI Innovation Challenge deadline coming up on December 9th, LSN would like to encourage you to put your company in the spotlight. We’ve seen some very impressive applications thus far, and we hope to receive many more by the deadline next week. We’re excited to get this look into emerging technologies, and LSN’s scientific review board will assess every application to select the 30 best entrants to be part of the RESI Innovation Challenge.

As always, we welcome a broad variety of life science startups to apply; past RESI winners have come from all over the map, including companies developing products in biotech, healthcare IT, diagnostics, and personalized medicine. With the deadline a week away, we’re looking forward to receiving your application.

RESI-SF-2016-RESI-Innovation-Challenge

Tags:

RESI Panel Announcement: Diagnostic Investors

3 Dec

By Nicholas Civitarese, Research Analyst, LSN

nick-wp

The amount of capital being invested in medical technology and diagnostics is at its highest point since 2008. However, companies in the diagnostics space face some unique challenges in the fundraising landscape.

To inform your fundraising campaign’s direction, Life Science Nation is pleased to announce a panel of six investors with expertise in the diagnostics space for RESI San Francisco on January 12th. Moderated by Akhil Saklecha, Partner at Artiman Ventures, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these diagnostic investors – including best practices for building relationships with diagnostic investors as well as advice on making sure your diagnostic company is positioned as a strong investment opportunity.

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , , ,

← Older Entries
Newer Entries →